Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis

被引:386
作者
Cipriani, Andrea [1 ]
Barbui, Corrado
Salanti, Georgia [2 ]
Rendell, Jennifer [3 ]
Brown, Rachel [3 ]
Stockton, Sarah [3 ]
Purgato, Marianna
Spineli, Loukia M. [2 ]
Goodwin, Guy M. [3 ]
Geddes, John R. [3 ]
机构
[1] Univ Verona, WHO Collaborating Ctr Res & Training Mental Hlth, Dept Publ Hlth & Community Med,Policlin G B Rossi, Dept Med & Publ Hlth,Sect Psychiat & Clin Psychol, I-37134 Verona, Italy
[2] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece
[3] Univ Oxford, Dept Psychiat, Oxford, England
基金
英国经济与社会研究理事会; 英国医学研究理事会; 欧洲研究理事会;
关键词
COST-EFFECTIVENESS; DISORDER; GUIDELINES; COMBINATION; MONOTHERAPY; RELAPSE; UPDATE; MOOD; RISK;
D O I
10.1016/S0140-6736(11)60873-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Conventional meta-analyses have shown inconsistent results for efficacy of pharmacological treatments for acute mania. We did a multiple-treatments meta-analysis, which accounted for both direct and indirect comparisons, to assess the effects of all antimanic drugs. Methods We systematically reviewed 68 randomised controlled trials (16 073 participants) from Jan 1, 1980, to Nov 25, 2010, which compared any of the following pharmacological drugs at therapeutic dose range for the treatment of acute mania in adults: aripiprazole, asenapine, carbamazepine, valproate, gabapentin, haloperidol, lamotrigine, lithium, olanzapine, quetiapine, risperidone, topiramate, and ziprasidone. The main outcomes were the mean change on mania rating scales and the number of patients who dropped out of the allocated treatment at 3 weeks. Analysis was done by intention to treat. Findings Haloperidol (standardised mean difference [SMD] -0.56 [95% CI -0.69 to -0.43]), risperidone (-0.50 [-0.63 to -0.38]), olanzapine (-0.43 [-0.54 to -0.32], lithium (-0.37 [-0.63 to -0.11]), quetiapine (-0.37 [-0.51 to -0.23]), aripiprazole (-0.37 [-0.51 to -0.23]), carbamazepine (-0.36 [-0.60 to -0.11], asenapine (-0.30 [-0.53 to -0.07]), valproate (-0.20 [-0.37 to -0.04]), and ziprasidone (-0.20 [-0.37 to -0.03]) were significantly more effective than placebo, whereas gabapentin, lamotrigine, and topiramate were not. Haloperidol had the highest number of significant differences and was significantly more effective than lithium (SMD -0.19 [95% CI -0.36 to -0.01]), quetiapine (-0.19 [-0.37 to 0.01]), aripiprazole (-0.19 [-0.36 to -0.02]), carbamazepine (-0.20 [-0.36 to -0.01]), asenapine (-0.26 [-0.52 to 0.01]), valproate (-0.36 [-0.56 to -0.15]), ziprasidone (-0.36 [-0.56 to -0.15]), lamotrigine (-0.48 [-0.77 to -0.19]), topiramate (-0.63 [-0.84 to -0.43]), and gabapentin (-0.88 [-1.40 to -0.36]). Risperidone and olanzapine had a very similar profile of comparative efficacy, being more effective than valproate, ziprasidone, lamotrigine, topiramate, and gabapentin. Olanzapine, risperidone, and quetiapine led to significantly fewer discontinuations than did lithium, lamotrigine, placebo, topiramate, and gabapentin. Interpretation Overall, antipsychotic drugs were significantly more effective than mood stabilisers. Risperidone, olanzapine, and haloperidol should be considered as among the best of the available options for the treatment of manic episodes. These results should be considered in the development of clinical practice guidelines.
引用
收藏
页码:1306 / 1315
页数:10
相关论文
共 30 条
[1]   Bayesian methods for evidence synthesis in cost-effectiveness analysis [J].
Ades, AE ;
Sculpher, M ;
Sutton, A ;
Abrams, K ;
Cooper, N ;
Welton, N ;
Lu, GB .
PHARMACOECONOMICS, 2006, 24 (01) :1-19
[2]  
[Anonymous], 2006, NICE CLIN GUID
[3]   Simultaneous comparison of multiple treatments: combining direct and indirect evidence [J].
Caldwell, DM ;
Ades, AE ;
Higgins, JPT .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 331 (7521) :897-900
[4]   Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis [J].
Cipriani, Andrea ;
Furukawa, Toshiaki A. ;
Salanti, Georgia ;
Geddes, John R. ;
Higgins, Julian P. T. ;
Churchill, Rachel ;
Watanabe, Norio ;
Nakagawa, Atsuo ;
Omori, Ichiro M. ;
McGuire, Hugh ;
Tansella, Michele ;
Barbui, Corrado .
LANCET, 2009, 373 (9665) :746-758
[5]   Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials [J].
Correll, Christoph U. ;
Sheridan, Eva M. ;
DelBello, Melissa P. .
BIPOLAR DISORDERS, 2010, 12 (02) :116-141
[6]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188
[7]   Checking consistency in mixed treatment comparison meta-analysis [J].
Dias, S. ;
Welton, N. J. ;
Caldwell, D. M. ;
Ades, A. E. .
STATISTICS IN MEDICINE, 2010, 29 (7-8) :932-944
[8]   Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial [J].
Geddes, John R. ;
Goodwin, Guy M. ;
Rendell, Jennifer ;
Azorin, Jean-Michel ;
Cipriani, Andrea ;
Ostacher, Michael J. ;
Morriss, Richard ;
Alder, Nicola ;
Juszczak, Ed ;
Lewis, Shon ;
Attenburrow, Mary-Jane ;
Carter, Brigid ;
Hainsworth, Jane ;
Healey, Christine ;
Stevens, Will ;
Van der Cucht, Emma ;
Young, Heather ;
Davies, Christina ;
Peto, Richard ;
Barnes, Thomas R. E. ;
Curtis, Vivienne ;
Johnson, Tony ;
de Silva, Asita ;
Marven, Michael ;
Berry, David ;
Arif, Mohammed ;
Bruce, Janet ;
Drybala, Gary ;
Hayden, Enda ;
Jhingan, Harsh P. ;
Marudkar, Mangesh ;
Hillier, Richard ;
Barrett, Sara ;
Lidder, Jasvinder Sing ;
McCartney, Mark ;
Middleton, Hugh ;
Ononve, Frank ;
Solanki, Ramesh D. ;
Agell, Ignasi ;
Anjum, Rubina ;
Hunt, Neil ;
Jones, Peter ;
Ramana, Rajim ;
Chase, Jeremy ;
Ayuba, Larry ;
Macmillan, Iain ;
Michael, Albert ;
Frangou, Sophia ;
Gijsman, Harm ;
Parker, Elizabeth .
LANCET, 2010, 375 (9712) :385-395
[9]   Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology [J].
Goodwin, G. M. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2009, 23 (04) :346-388
[10]   The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania [J].
Grunze, Heinz ;
Vieta, Eduard ;
Goodwin, Guy M. ;
Bowden, Charles ;
Licht, Rasmus W. ;
Moeller, Hans-Juergen ;
Kasper, Siegfried .
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2009, 10 (02) :85-116